Paragon Private Wealth Management LLC Makes New $712,000 Investment in DexCom, Inc. $DXCM

Paragon Private Wealth Management LLC purchased a new stake in DexCom, Inc. (NASDAQ:DXCM) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 10,567 shares of the medical device company’s stock, valued at approximately $712,000.

A number of other hedge funds also recently made changes to their positions in the business. Plato Investment Management Ltd bought a new stake in shares of DexCom in the 2nd quarter worth about $782,000. BOKF NA lifted its holdings in DexCom by 175.7% during the 4th quarter. BOKF NA now owns 35,314 shares of the medical device company’s stock valued at $2,344,000 after purchasing an additional 22,505 shares during the last quarter. Stephens Investment Management Group LLC boosted its position in DexCom by 21.1% in the fourth quarter. Stephens Investment Management Group LLC now owns 1,042,801 shares of the medical device company’s stock valued at $69,211,000 after buying an additional 181,701 shares in the last quarter. Goodman Advisory Group LLC acquired a new position in DexCom in the fourth quarter valued at about $1,293,000. Finally, Aurora Investment Counsel bought a new stake in DexCom during the second quarter worth about $2,340,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Trading Down 0.5%

NASDAQ:DXCM opened at $89.69 on Thursday. The firm has a market capitalization of $33.85 billion, a price-to-earnings ratio of 35.45, a PEG ratio of 1.51 and a beta of 1.42. The business’s 50-day moving average price is $80.47 and its two-hundred day moving average price is $72.10. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $92.59.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The business had revenue of $1.31 billion during the quarter, compared to analysts’ expectations of $1.29 billion. During the same period in the prior year, the business earned $0.48 EPS. DexCom’s revenue for the quarter was up 13.1% compared to the same quarter last year. On average, equities analysts expect that DexCom, Inc. will post 2.64 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Truist Financial set a $93.00 target price on shares of DexCom and gave the company a “buy” rating in a research note on Friday, July 31st. Robert W. Baird set a $105.00 price target on DexCom in a report on Friday, July 31st. Royal Bank Of Canada boosted their price objective on DexCom from $85.00 to $90.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. Wells Fargo & Company increased their target price on DexCom from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. Finally, Deutsche Bank Aktiengesellschaft started coverage on DexCom in a research note on Tuesday, June 23rd. They issued a “buy” rating and a $86.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, DexCom currently has an average rating of “Moderate Buy” and an average price target of $88.71.

Insider Activity at DexCom

In other DexCom news, EVP Sadie Stern sold 2,565 shares of DexCom stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $88.37, for a total value of $226,669.05. Following the sale, the executive vice president owned 126,043 shares of the company’s stock, valued at $11,138,419.91. This trade represents a 1.99% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $75.55, for a total value of $128,435.00. Following the completion of the sale, the executive vice president owned 106,353 shares in the company, valued at approximately $8,034,969.15. This trade represents a 1.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 65,777 shares of company stock valued at $4,950,714. 0.28% of the stock is owned by insiders.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.